<qa>  What is the name of the two drugs that are important in MCL?The combination of lenalidomide with bortezomib has not been studied in patients with MCL, but feasibility and tolerability has been demonstrated in patients with multiple myeloma. Thus, almost every 2-drug combination of rituximab, lenalidomide, and bortezomib has been tested, or is being tested. We hypothesize that all three drugs are important in MCL, and therefore propose to combine all 3 agents rituximab, bortezomib, and lenalidomide in a schedule that is convenient to lymphoma patients. 